

2/20/2024

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Iovance Biotherapeutics Manufacturing, LLC is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on 2/19/2024. The new product being launched is:

AMTAGVI™ (lifileucel) suspension for intravenous infusion

73776-0001-11

Sincerely,

Bill Hershfield

Head of Market Access Operations, Distribution and Pricing

Iovance Biotherapeutics, Inc.